U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H19NO2
Molecular Weight 233.3062
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPHENIDATE

SMILES

[H][C@]1(CCCCN1)[C@@H](C(=O)OC)C2=CC=CC=C2

InChI

InChIKey=DUGOZIWVEXMGBE-STQMWFEESA-N
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C14H19NO2
Molecular Weight 233.3062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Methylphenidate is a CNS stimulant approved for the treatment of narcolepsy and attention deficit hyperactivity disorder. The drug is believed to bind the dopamine transporter in the presynaptic cell membrane, thereby blocking the reuptake of dopamine and causing an increase in extracellular dopamine levels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

-4.62153613E11
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

-4.62153613E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 ng/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.8 ng × h/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
unknown, unknown
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Other AEs: Abuse...
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Other AEs: Hypertension, Tachycardia...
Other AEs:
Hypertension (grade 1)
Tachycardia (grade 1)
Confusion
Irritability
Agitation
Hallucinations
Sources:
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.6%)
Nausea (1.6%)
Hot flushes (1.6%)
Panic attack (1.6%)
Nausea (1.6%)
Vomiting (1.6%)
Dizziness (1.6%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Fatigue, Lethargy...
AEs leading to
discontinuation/dose reduction:
Fatigue (1.5%)
Lethargy (1.5%)
Hypomania (1.5%)
Anger (1.5%)
Anxiety (1.5%)
Migraine (1.5%)
Depression (1.5%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
AEs

AEs

AESignificanceDosePopulation
Abuse
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Agitation
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Confusion
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hallucinations
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Irritability
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hypertension grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Tachycardia grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Dizziness 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Headache 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hot flushes 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Panic attack 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Vomiting 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anger 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anxiety 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Depression 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Fatigue 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hypomania 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Lethargy 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Migraine 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Letter: Methylphenidate reaction.
1975 Jun
One-year follow-up of hyperactive boys treated with imipramine or methylphenidate.
1975 Mar
Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.
1978 Dec
Cocaine-associated stroke: three cases and rehabilitation considerations.
2000 Apr
Cerebral arteritis following methylphenidate use.
2000 Apr
[Methylphenidate, tics and compulsions].
2000 Mar-Apr
Blockade of sensitization to methylphenidate by MK-801: partial dissociation from motor effects.
2001
Pharmacotherapeutic management of autism.
2001 Apr
Understanding Rx options for the youngest patients.
2001 Aug
Concerns about Ritalin.
2001 Aug
Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder.
2001 Feb
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.
2001 Feb
Obsessive-compulsive symptoms secondary to methylphenidate treatment.
2001 Feb
Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.
2001 Feb
Ritalin: mom's little helper. A disorder long linked to sons migrates up the family tree.
2001 Feb 12
Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action.
2001 Feb 15
Methylphenidate works by increasing dopamine levels.
2001 Feb 3
Benefit of long-term stimulants on driving in adults with ADHD.
2001 Jan
Frontal lobe disinhibition, Rett syndrome and attention deficit hyperactivity disorder.
2001 Jan
What's all the fuss about Ritalin?
2001 Jan
Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.
2001 Jan 15
Questioning the treatment for ADHD.
2001 Jan 26
[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
2001 Jul
A comparison of the visual symptoms between ADD/ADHD and normal children.
2001 Jul
Advances in paediatric neuropsychopharmacology: an overview.
2001 Jun
Comparison in symptoms between aged and younger patients with narcolepsy.
2001 Jun
Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link?
2001 Jun
Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans.
2001 Jun
Practice parameters for the treatment of narcolepsy: an update for 2000.
2001 Jun 15
Commentary on Greene and Ablon: What does the MTA study tell us about effective psychosocial treatment for ADHD?
2001 Mar
Comprehensive versus matched psychosocial treatment in the MTA study: conceptual and empirical issues.
2001 Mar
What does the MTA study tell us about effective psychosocial treatment for ADHD?
2001 Mar
Case study: sexual hyperactivity treated with psychostimulants in familial male precocious puberty.
2001 Mar
[Problem in methylphenidate use for the treatment of attention deficit hyperactivity disorder in Japan].
2001 Mar
Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.
2001 Mar
Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.
2001 Mar
Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus.
2001 Mar 1
[Prescription of central nervous system stimulants].
2001 Mar 20
Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution.
2001 May
Methylphenidate sensitization is modulated by valproate.
2001 May 25
Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study.
2001 May-Jun
Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
2001 May-Jun
Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants.
2001 Spring
Patents

Sample Use Guides

Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In children the starting dose is 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
Route of Administration: Oral
Murine neural stem cells were treated directly after seeding to the cover-slip using different concentration (0 nM, 1 nM, 10 nM, 100 nM) of methylphenidate. The drug was found to enhance neuronal differentiation and inhibit neural proliferation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:16:30 UTC 2023
Edited
by admin
on Fri Dec 15 16:16:30 UTC 2023
Record UNII
207ZZ9QZ49
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLPHENIDATE
HSDB   II   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
METHYLPHENIDATE [VANDF]
Common Name English
α-Phenyl-2-piperidineacetic acid methyl ester
Systematic Name English
METHYLPHENIDATE [ORANGE BOOK]
Common Name English
methylphenidate [INN]
Common Name English
METHYLPHENIDATE EXTENDED RELEASE
Common Name English
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER
Common Name English
METHYLPHENIDATE [HSDB]
Common Name English
PRC-063
Common Name English
THREO-DL-METHYLPHENIDATE
Common Name English
COTEMPLA XR-ODT
Brand Name English
Methylphenidate [WHO-DD]
Common Name English
DAYTRANA
Brand Name English
METHYLPHENIDATE [MI]
Common Name English
METHYLPHENIDATE [MART.]
Common Name English
METHYLPHENIDATE [II]
Common Name English
METHYLPHENIDATE [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK547941
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
WHO-VATC QN06BA04
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
DEA NO. 1724
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
NDF-RT N0000175739
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
NDF-RT N0000175729
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
WHO-ATC N06BA04
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
Code System Code Type Description
INN
485
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
ChEMBL
CHEMBL796
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
DRUG CENTRAL
1767
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
CHEBI
6887
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
DRUG BANK
DB00422
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
EVMPD
SUB08870MIG
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
FDA UNII
207ZZ9QZ49
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
DAILYMED
207ZZ9QZ49
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
RXCUI
6901
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY RxNorm
SMS_ID
100000080907
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
MESH
D008774
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
HSDB
113-45-1
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
ECHA (EC/EINECS)
204-028-6
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023299
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
CAS
20748-11-2
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
IUPHAR
7236
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
USAN
PP-76
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
MERCK INDEX
m7453
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY Merck Index
LACTMED
Methylphenidate
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
WIKIPEDIA
METHYLPHENIDATE
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
PUBCHEM
10657292
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
NCI_THESAURUS
C62045
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
PRIMARY
CAS
113-45-1
Created by admin on Fri Dec 15 16:16:30 UTC 2023 , Edited by admin on Fri Dec 15 16:16:30 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY